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Progression of atherosclerosis with carnitine
supplementation: a randomized controlled trial
in the metabolic syndrome
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Patrick A. Norman3, Andrew G. Day3, Murray F. Matangi4, Erin D. Michos5, Stephen A. LaHaye6,
Fraser W. Saunders7 and J. David Spence8

Abstract
Background: L-carnitine (L-C), a ubiquitous nutritional supplement, has been investigated as a potential therapy for
cardiovascular disease, but its effects on human atherosclerosis are unknown. Clinical studies suggest improvement
of some cardiovascular risk factors, whereas others show increased plasma levels of pro-atherogenic trimethylamine
N-oxide. The primary aim was to determine whether L-C therapy led to progression or regression of carotid total
plaque volume (TPV) in participants with metabolic syndrome (MetS).
Methods: This was a phase 2, prospective, double blinded, randomized, placebo-controlled, two-center trial. MetS
was defined as ≥ 3/5 cardiac risk factors: elevated waist circumference; elevated triglycerides; reduced HDL-choles‑
terol; elevated blood pressure; elevated glucose or HbA1c; or on treatment. Participants with a baseline TPV ≥ 50 mm3
were randomized to placebo or 2 g L-C daily for 6 months.
Results: The primary outcome was the percent change in TPV over 6 months. In 157 participants (L-C N = 76, pla‑
cebo N = 81), no difference in TPV change between arms was found. The L-C group had a greater increase in carotid
atherosclerotic stenosis of 9.3% (p = 0.02) than the placebo group. There was a greater increase in total cholesterol
and LDL-C levels in the L-C arm.
Conclusions: Though total carotid plaque volume did not change in MetS participants taking L-C over 6-months,
there was a concerning progression of carotid plaque stenosis. The potential harm of L-C in MetS and its association
with pro-atherogenic metabolites raises concerns for its further use as a potential therapy and its widespread avail‑
ability as a nutritional supplement.
Trial registration: ClinicalTrials.gov, NCT02117661, Registered April 21, 2014, https://clinicaltrials.gov/ct2/show/NCT02
117661.
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Background
Metabolic syndrome (MetS) is a group of cardiovascular risk factors that when combined increase the risk of
heart disease and stroke. The risk factors include obesity, hypertension, high blood glucose, low high-density
lipoprotein cholesterol (HDL-C), and high triglycerides
[1]. Any combination of three risk factors determines
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regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this
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predisposition to MetS. Individuals with MetS are three
times more likely to have a heart attack or stroke due to
atherosclerosis [2].
L-carnitine (L-C) is a non-essential dietary amino
acid synthesized from lysine and methionine, involved
in adenosine triphosphate and energy generation [3–5].
L-C is found to be naturally occurring in red meat, dairy,
and poultry products [6]. Ubiquitous to the billion dollar global supplement industry, L-C usage is unregulated,
and a widely available ingredient touted in energy drinks,
pre-workout supplements, and a large proportion of
other products found at health food stores [7, 8].
L-C and its short esters affect lipid metabolism by acting as obligatory cofactors for oxidation of fatty acids and
facilitating the transport of long-chain fatty acids across
the mitochondrial membrane. Oral administration of L-C
has been shown to help in lipid metabolism [9, 10], insulin-dependent glucose disposal, and blood pressure control [11]; suggesting a potential favorable influence on the
cardiovascular risk factors associated with MetS. However, there has been debate as to whether L-C can provide
benefit to individuals with cardiovascular disease, and its
effects remain unknown with no randomized controlled
trials assessing direct effects on human atherosclerosis
to date. Though epidemiological studies [12] and randomized trials [9] have suggested a possible reduction of
cardiovascular risk factors following treatment, other
animal and human studies have shown that L-C may
increase pro-atherogenic metabolites such as trimethylamine oxide (TMAO) [13–15]. Thus, a randomized controlled trial directly assessing atherosclerosis in patients
at risk of cardiovascular disease is required.
Three dimensional (3D) carotid ultrasound is a sensitive method of quantifying atherosclerotic plaque progression and is capable of directly detecting changes in
atherosclerotic plaque progression (burden and degree
of stenosis) within three months [16, 17]. The purpose
of this study was to determine if L-C causes progression
or regression of carotid plaque burden and occlusion in
MetS participants, by directly quantifying the change in
plaque volume and stenosis over six months of treatment.

study groups. Randomization was performed using permuted blocks of variable size and stratified by site.

Methods

Inclusion criteria

Study design

This was an investigator-initiated phase 2, prospective, parallel, double blinded, randomized, placebo-controlled, two-center trial (ClinicalTrials.gov Identifier:
NCT02117661, the ECoM trial). Eligible patients were
randomized following a two-step inclusion process
and randomized (first dose) within four weeks of initial
carotid ultrasound. A centralized web-based randomization system was used to randomly allocate participants to

Trial participants

Patients, followed in clinics for cardiovascular disease
prevention, fulfilling diagnostic criteria for MetS were
recruited from two centres: The Stroke Prevention and
Atherosclerosis Research Centre (SPARC) in London,
Ontario, and the Cardiovascular Imaging Network at
Queen’s (CINQ), Kingston, Ontario. Following randomization, participants entered a six-month treatment period
with either 2 g/day of oral L-C or placebo (cellulose),
both given in divided doses in the morning (2 × 500 mg)
and evening (2 × 500 mg). To maintain blinding, the placebo was identical in appearance to the L-C capsule, but
contained cellulose powder as the ingredient. Both capsules were prepared by the Commissioner’s Pharmacy,
London, ON and Wynand Bekker Pharmacy Ltd.-Shoppers Drug Mart, Belleville, ON. All batches were tested
for contaminants (Analytical Services Unit at Queen’s
and Canadian Analytical Laboratories Inc).
MetS patients were assessed for inclusion and exclusion
in two steps: STEP 1: Participants meeting initial eligibility screening were invited to participate, approached for
informed consent, and provided blood sample (fasting)
for confirmation of MetS. STEP 2: Participants received
a 3D carotid ultrasound. A minimal total plaque volume
(TPV) of ≥ 50 mm3 was required for eligibility. Participant meeting both step 1 (confirmation of MetS by blood
and waist measurement) and step 2 (minimum plaque
volume) were selected for randomization.
Participants were randomized within 2 weeks of the 1st
visit and given the first dose. Randomization codes and
blinding were coordinated by the site’s designated pharmacist. A blinded study coordinator at each site enrolled
and assigned participants to a kit number based on the
web-based system output at the randomization visit.
Research coordinators, participants, and investigators
were blinded to allocation. The CONSORT diagram is
presented in Fig. 1.

STEP 1: Men and women, > 18 years, meeting the criteria for clinical diagnosis of MetS, according to the International Diabetes Federation [16], where any 3 or more
of the 5 following risk factors constituted a diagnosis of
MetS:
(a) Elevated waist circumference: males > 102 cm and
females > 88 cm.
(b) Elevated triglycerides: > 1.7 mmol/L (150 mg/dL).
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(c) Reduced HDL-C: < 1.0 mmol/L (40 mg/dL) in
males; < 1.3 mmol/L (50 mg/dL) in females or
treated.
(d) Elevated BP: Systolic > 130 and/or diastolic > 85 mm
Hg or treated.
(e) Elevated fasting glucose: > 5.6 mmol/L (100 mg/dL),
or HbA1c ≥ 6.2%, or treated.
STEP 2: Carotid ultrasound confirmation of a baseline
TPV ≥ 50 mm3 by 3D US, to ensure sufficiently detectable plaque.
Exclusion criteria

1. A change in statin or diabetes therapy dosing in the
previous three months;
2. Unstable or untreated arrhythmia, angina or heart
attack; Symptomatic heart failure;
3. Severe liver disease, severe anemia, severe
abnormal blood biochemistries, or renal failure
(eGFR < 50 mL/min/1.73m2);
4. Endocrine disorders;
5. A condition expected to limit survival to less than
6-months;
6. A condition limiting adherence (i.e. alcoholism,
drug addiction, known poor adherence);
7. Concomitant treatment with: anticonvulsants, L-C
or derivatives, Acenocoumarol, Warfarin, > 1 g fish
oil, and/or drugs that affect insulin sensitivity, and/
or thyroid treatment;
8. A seizure disorder or at risk of seizure; treatments
for cancer or HIV infection (secondary L-C deficiency);
9. Currently pregnant or breastfeeding;
10. History of allergy to L-C or derivatives;
11. Vegetarianism due to potential for altered L-C
metabolism;
12. Previous carotid surgery.
Study visits

Fig. 1 CONSORT participant flow diagram

Following randomization, visits were at month 1, 3, and
6 (study exit). Carotid scans to assess plaque burden
were conducted at baseline and study exit. Participants’
weight, waist circumference, and food (portions of red
meat consumed per week) and exercise diaries were collected. An average of 3 diaries were used for analysis.
Leftover pill counts were counted at each visit. Fasting
blood sample and 3D ultrasound were taken at baseline
and month 6 (or study exit if participant withdrew consent after the 3 month mark).
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Carotid ultrasound

A focussed carotid ultrasound limited to measuring
carotid intimal media thickening (CIMT) and plaque
measurements was conducted using a Philips Healthcare
IU22 system equipped with a L12-3 linear transducer for
2D and a VL13-5 transducer for 3D acquisition (Philips
Healthcare, Markham, ON, Canada). Identical equipment and methods were used at both sites. Images were
acquired on the left and right sides of the neck. The 3D
volume acquisition was performed using the 3D function,
set at an angle of 15° to 30°. Resolution speed was turned
down 1 notch counter clockwise and the harmonics
turned off. Gain or focus was optimized for each participant. Images were stored in DICOM format and analysed
offline by the core reading site (Kingston).
Carotid variables measured

CIMT, maximum plaque height (MPH), total plaque
area (TPA), total plaque volume (TPV), and maximum
area stenosis caused by the plaque were quantified using
QLAB version 10.2 (Philips Healthcare, Andover, MA,
USA). CIMT was measured using the automatic function
and averaged for both sides. Plaque height was measured
manually in the bulb/internal carotid artery region using
the caliper function, and the maximum height of either
side was used in the analysis. Plaque area was traced
manually and the total area of both sides added [18].
Plaque measurements were conducted as per the American Society of Echocardiography recommendations [19].
Plaque volume and lumen area reduction (stenosis)
in 3D was quantified using QLAB VPQ. The acquisition
video frames were analyzed in short-axis view of the
bifurcation towards the internal carotid artery (ICA) in
a series of image frames. The start (first frame) and end
(last frame) of the plaque was outlined using an ellipse
and set as “no plaque”, then a key frame in the center of
the plaque was outlined to represent “plaque”. Reference
key frames were manually modified as necessary. The
TPV and maximum area reduction were automatically
calculated. The sum of both right and left were added
to give the TPV. A greater maximum area reduction
(automatically calculated by the software) represented a
smaller lumen to plaque proportion (increased area stenosis) [19].
Statistics

Our sample size was based on the % difference of TPV
from baseline to six months. Based on six month studies
by Migrino et al. [20] and Tani et al. [21] measuring TPV,
we estimated the standard deviation of the % change in
TPV to be 11%. In a study by Ainsworth et al. [16] specifically designed to aid in estimating effect sizes for trials

Page 4 of 11

such as ours, it was estimated that after six months of
treatment with atorvastatin, average TPV would regress
by 180 mm3 from a baseline of 690 (i.e. a 26% reduction).
We considered an absolute reduction of 5.2% in TPV
(20% of 26% reduction observed with atorvastatin) to be
both plausible and minimally clinically important. We
required 72 completers per group to achieve 80% power
at a 2-sided alpha = 0.05 to detect a 5.2% absolute difference in the % change between groups. We required 80
patients per group to allow for up to 10% lost to follow
up.
The primary outcome of this study was the percent
change in the TPV between the baseline visit and the
study exit, 6 months later. Absolute changes are also
reported. Secondary analyses of changes in additional
plaque parameters were also assessed. A secondary
planned outcome assessment of changes in LDL density, registered on clinicaltrials.gov, was not assessed
due to the underdeveloped experimental nature of the
assay. Analysis of covariance (ANCOVA) with treatment
assignment as an indicator variable blocking by site and
controlling for baseline plaque measures as a covariate was used to estimate the within-arm change and
between-arm difference in change. The raw plaque measures were modeled to estimate the absolute change. Percent change (the primary outcome) within and between
treatment arms were estimated by modelling the log of
the ratio of the month 6 and baseline plaque measures
and then exponentiating the relevant model parameter estimates, subtracting one, and multiplying by 100.
Changes in clinical and biochemical characteristics were
analyzed using the Wilcoxon rank-sum test. False Discovery Rates (FDR) were used to address multiplicity of
hypothesis testing. Compliance was defined as the percentage of the study medication taken, based on returned
capsules.
Subgroup analyses were performed for TPV and stenosis to assess potential effect modification of: baseline
plaque levels (higher or lower than median), average
weekly red meat consumption (higher or lower than
median), sex (male or female), and study site. This analysis used the same ANCOVA model described above
except we added an interaction term between treatment
assignment and the given subgroup to estimate withinsubgroup treatment effects and obtain p values testing
for a difference in treatment effect between subgroups.
We did not control for baseline TPV or stenosis when
those variables defined the subgroups.
All analyses were performed using SAS Version 9.4
(SAS Institute Inc., Cary, NC, USA). A two-sided p
value < 0.05 was considered statistically significant.
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Results
Participant workflow

We studied the effects of L-C on carotid atherosclerosis
in participants with MetS. The first patient was screened
for inclusion on January 28, 2015. Between February 18,
2015 and January 6, 2017, 89 participants were randomized to L-C treatment, while 88 were randomized to a
placebo (N = 177) [Fig. 1]. Follow-up was 6-months from
randomization (end July 7, 2017). Of these, 76 and 81
participants from the L-C and placebo arms respectively,
had complete carotid scan data and were included in the
primary analysis (N = 157).
Participant characteristics

Both participant arms were well balanced on all characteristics, though the intervention arm contained a
slightly greater proportion of females than the placebo
arm (33.7% female vs 25.0% female, respectively; Table 1).
The two arms were reasonably well balanced with respect
to the presence of cardiovascular comorbidities (angina,
valvular disease, congestive heart failure, hypertension,
diabetes, hyperlipidemia, and cardiac revascularization),
with the placebo arm having marginally higher rates of
cardiac arrhythmia (19% vs 11%), myocardial infarction (MI) (39% vs 30%), and obesity (BMI ≥ 30 kg/m2

78% vs 66%). In terms of concomitant cardiac medications, the two arms were well balanced (statins [95% of
participants], angiotensin converting enzyme inhibitors,
angiotensin II receptor blockers, anti-platelet, anti-coagulation, diabetes medications, calcium channel blockers,
diuretics, anti-anginal, and nonsteroidal anti-inflammatory drugs—NSAIDs), though the placebo arm had more
participants on beta-blockers (49% vs 33%) and fewer
participants on alpha-blockers (7% vs 12%).
Compliance

Both arms had similarly high compliance to the study
treatment, with the average compliance across all
6 months being 95.4% and 95.7% in the intervention and
placebo arms, respectively. Above 80% compliance rates
were within 2% of each other for all months; with intervention ranging from 92.0% to 96.0%, and the placebo
ranging from 93.9% to 97.6%.
Safety

Known L-C adverse effects recorded included: gastrointestinal symptoms, a fishy body odour, and occurrence of
a seizure. Adverse events collected were: angina (change
in frequency), stroke, transient ischemic attack, MI, congestive heart failure, cardiac revascularization, cerebral

Table 1 Baseline clinical and blood characteristics
Variable

L-C
(n = 89)

Age (years), mean ± SD

Sex (male), N (%)

66.5 ± 8.2

59 (66.3)

Placebo
(n = 88)
66.3 ± 8.3

65 (73.9)

Total Cohort
(n = 177)
66.4 ± 8.2

124 (70.1)

Race/ethnicity (Caucasian), N (%)

87 (97.8)

87 (98.9)

174 (98.3)

WC (cm), mean ± SD

111.6 ± 12.8

112.8 ± 12.0

112.2 ± 12.4

Waist: Hip ratio, mean ± SD
2

BMI (kg/m ), mean ± SD

Current smoker, N (%)

1.0 ± 0.1

32.2 ± 5.7

12 (13.5)

1.0 ± 0.1

32.5 ± 5.2

8 (9.1)

1.0 ± 0.1

32.4 ± 5.4

20 (11.3)

HDL-C (mmol/L), median [IQR]

1.1 [0.9 to 1.3]

1.1 [1.0 to 1.3]

1.1 [1.0 to 1.3]

Triglycerides (mmol/L), median [IQR]

1.3 [0.9 to 1.8]

1.4 [0.9 to 1.9]

1.4 [0.9 to 1.9]

Glucose (mmol/L), median [IQR]

6.0 [5.2 to 7.2]

5.9 [5.2 to 6.7]

6.0 [5.2 to 7.0]

HbA1C (%), median [IQR]

6.2 [5.9 to 7.3]

6.5 [5.8 to 7.0]

6.4 [5.9 to 7.1]

eGFR (mL/min/1.73 m
 2), mean ± SD

Systolic BP (mmHg), mean ± SD

Diastolic BP (mmHg), mean ± SD

Total of MetS criteria

83.3 ± 17.0

130.5 ± 18.1

76.1 ± 10.1

80.7 ± 17.0

132.6 ± 18.8

78.1 ± 10.5

82.0 ± 17.0

131.5 ± 18.4

77.1 ± 10.4

3, N (%)

24 (27.0)

20 (22.7)

44 (24.9)

4, N (%)

45 (50.6)

47 (53.4)

92 (52.0)

5, N (%)
Weekly consumed servings of red meat, mean ± SD

20 (22.5)

21 (23.9)

41 (23.2)

2.9 ± 2.9

2.8 ± 2.3

2.8 ± 2.6

p values are not presented due to the nature of randomization. For HDL-C, to convert from mmol/L to mg/dL, multiply by 38.67. For triglycerides, to convert
from mmol/L to mg/dL, multiply by 88.57
BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; HbA1C, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; L-C,
L-carnitine; MetS, metabolic syndrome, WC, waist circumference
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revascularization, peripheral revascularization, high
blood pressure and diabetes (new diagnosis only). No
important differences between arms in adverse effects or
adverse events were observed at any time point. No seizure occurred.
Serious adverse events (SAEs) were collected at each
visit and reported according to institutional policies. A
total of seven participants had a serious adverse event
(four in the intervention arm, three in the placebo arm).
Only one SAE was deemed “unlikely related” to the intervention, with the rest deemed “not related”. The SAE
deemed “unlikely related” was in the placebo arm.
Outcomes

Baseline plaque burden was well balanced between
groups (Additional file 1: Table S1). The changes in
plaque variables were calculated as the absolute and percent change from baseline to month 6 (Table 2). Figure 2
illustrates an example of the quantification method for
TPV and stenosis. No statistically significant difference
between arms was found for either absolute or percent
TPV change. However, there was a significant between
group difference for an increase in carotid arterial plaque
stenosis (significant progression). Specifically, the %
change of in the L-C intervention arm was 9.3% (p = 0.02)
greater than in the placebo arm, which corresponded to
an absolute between arm difference of 2.7% (p = 0.03).
Clinical characteristics and biochemical values from
baseline and month 6 were compared and the change
in median calculated (Additional file 1: Table S2). From
baseline to 6 months, the two arms were found to be

significantly different with regard to change in total
carnitine, free carnitine, magnesium, total cholesterol,
LDL-C, waist: hip ratio, systolic blood pressure, diastolic
blood pressure, and meat consumption. However, only
total carnitine, free carnitine (due to L-C supplementation), and magnesium change maintained a false discovery rate (FDR) of < 0.05 after adjusting for multiplicity of
outcomes.
We performed subgroup analyses to determine if the
treatment effect of L-C on TPV or maximum area stenosis differed by red meat consumption, baseline stenosis, baseline TPV, recruitment site, sex, or eGFR. There
were no significant between-arm differences in TPV for
any subgroups (data not shown). Compared to the placebo arm, the L-C arm had a significantly greater percent increase in stenosis among patients who ate less
red meat (percent difference 15.2%; p = 0.01), had lower
baseline stenosis (15.2%, p = 0.01), had lower baseline
TPV (15.8%; p = 0.01), were males (9.4%; p = 0.046) and
had high eGFR (11.3%; p = 0.01), while there were no
significant between arm differences in the complement
subgroups. However, no tests for treatment arm by subgroup interactions were statistically significant (Additional file 1: Table S3 and Fig. 3).

Discussion
This randomized controlled trial is the first to directly
demonstrate a measurable progression in the degree
atherosclerotic carotid plaque stenosis in response to
carnitine supplementation over a 6-month period. No
previous studies have assessed the direct effects of L-C

Table 2 Primary outcome total plaque volume percent change and absolute change from baseline to month 6 and exploratory
plaque variables
Variable

L-C
Mean change
(95%CI)

L-C
p value

Placebo
Mean Change
(95%CI)

Placebo p value

Between-Arm Diff.
Mean (95%CI)

0.44

− 1.2 (− 5.3 to 3.0)

BetweenArm Diff
p value

Percent change
TPV (%)
Stenosis (%)

− 2.4 (− 5.3 to 0.6)

4.6 (− 0.7 to 10.3)

0.12
0.09

− 1.2 (− 4.0 to 1.8)

− 4.3 (− 9.0 to 0.7)

0.09

9.3 (1.6 to 17.6)

0.56
0.02*

CIMT (%)

0.70 (− 1.8 to 3.3)

0.58

0.40 (− 2.0 to 2.9)

0.75

0.30 (− 3.2 to 3.9)

0.86

MPH (%)

0.1 (− 3.5 to 3.9)

0.95

2.8 (− 0.9 to 6.6)

0.14

0.32

− 1.7 (− 6.7 to 3.6)

0.52

− 1.5 (− 6.3 to 3.6)

0.57

− 2.6 (− 7.6 to 2.6)

− 0.2 (− 7.3 to 7.4)

0.93

− 8.0 (− 24.0 to 8.0)

TPA (%)
Absolute change
TPV (mm3)
Stenosis (%)

− 7.5 (− 18.9 to 4.0)
1.6 (− 0.2 to 3.4)

0.20
0.07

0.5 (− 10.6 to 11.6)
− 1.1 (− 2.8 to 0.7)

0.22

CIMT (mm)

0.0 (− 0.0 to 0.0)

0.58

0.0 (− 0.0 to 0.0)

0.43

MPH (mm)

0.0 (− 0.1 to 0.1)

0.79

0.1 (0.0 to 0.3)

0.046*

TPA (mm2)

− 0.7 (− 3.3 to 1.9)

0.60

− 0.3 (− 2.8 to 2.3)

Statistical test: analysis of covariance controlling for site and baseline

0.83

2.7 (0.2 to 5.2)

− 0.0 (− 0.0 to 0.0)

− 0.1 (− 0.3 to 0.1)

− 0.4 (− 4.1 to 3.3)

CIMT, carotid intima-media thickness; L-C, L-carnitine; MPH, maximum plaque height; TPA, total plaque area; TPV, total plaque volume
*Significant

0.95
0.33
0.03*
0.88
0.23
0.82
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Fig. 2 Quantification of carotid arterial plaque acquired by three-dimensional ultrasound. Philips VPQ software was used to assess plaque in 3D. A
cross section of the vessel demonstrates a percent lumen reduction (stenosis) of 36% at baseline compared to 47% at month 6

therapy on atherosclerotic plaque, as conducted here;
however, other recent work has indirectly suggested an
unfavourable association between L-C and cardiovascular risk factors [22, 23]. Given the widespread availability
of carnitine and its unregulated usage in the general population, this carefully conducted clinical trial has significant implications for cardiovascular risk of populations.
Previous studies, though not RCT, have also raised concerns with respect to L-C and association with cardiovascular risk factors. Gao et al. [22] recently conducted a
cross-sectional study in 1,081 participants in Newfoundland, Canada to determine correlations between serum
carnitine levels and cardiovascular markers. Though not
all participants met the criteria for MetS, serum carnitine levels (not taking L-C supplements) were associated
with components of MetS: serum triglycerides (r = 0.13)
and serum insulin (r = 0.12) in males with normal fasting
glucose and with serum triglycerides (r = 0.14) in hyperglycemic males. In females, positive correlations were
identified between serum L-C and obesity, total cholesterol, glucose, insulin, and insulin resistance in those

with normal fasting glucose level, but not if hyperglycemic. Similarly, our placebo-controlled trial confirms an
increase in total cholesterol and LDL-C levels in participants taking L-C, suggesting a potential mechanism linking L-C to the risk of increased atherosclerosis.
The pro-atherogenic effects of L-C therapy observed
by our work and others, may be mediated through an
increased production of TMAO [13]. Samulak et al. [24]
showed greater TMAO production in women randomized to 1500 mg L-C for 6 months, compared to placebo (N = 18). Neither lipid profiles nor inflammatory
markers were modified by either the carnitine supplementation or the washout period. TMAO levels returned
to normal within 4 months of supplement cessation. As
these were healthy women, our findings suggest a different effect or mechanism in individuals with MetS.
The pro-atherogenic effects of L-C and TMAO are relevant to the recommendations by the American Heart
Association and other Societies to decrease red meat
consumption in favour of other lean protein sources [25].
The carnitine-TMAO pathway has been suggested as a
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Fig. 3 Forest plot of stratified sub-analysis of percent change in stenosis. Although we found significant differences in percent increase of carotid
stenosis within sub-groups, no tests for treatment arm by sub-group interactions reached p < 0.05. LC, L-carnitine. N = 157

possible explanation for increased atherosclerotic risk
in red meat eaters [6, 13]. Wang et al. [23] demonstrated
that switching from red meat consumption to white meat
or non-meat protein reduced plasma and urine TMAO
over one month. Red meat ingestion reduced fractional
renal excretion of TMAO, but increased fractional renal
excretion of carnitine and two additional gut microbiotagenerated metabolites of carnitine: c-butyrobetaine, and
crotonobetaine. Red meat or white meat (vs. non-meat)
increased TMA and TMAO production from carnitine,
but not choline. Interestingly, we observed an increase in
the degree of atherosclerotic carotid stenosis in the L-C
group who consumed less red meat (< 2.8 servings per
week, 15.2% increase) compared to placebo, but not in
the high meat-eating group. However, the test for interaction did not reach p < 0.05. Nevertheless, it may be that
low meat eaters are less adapted to processing carnitine

intake than high meat eaters. The mechanism associated
with L-C may have been amplified in participants who do
not habitually eat large amounts of red meat, as the overall change in TMAO levels may have been greater suggesting a future avenue of further study.
Though our study indicated an adverse effect of L-C on
carotid stenosis (degree of atherosclerotic occlusion), the
overall plaque volumes measured did not progress, likely
because plaque burden and stenosis are different phenotypes [26]. Due to compensatory enlargement (Glagov’s
phenomenon) [27], arteries enlarge with progression
of plaque, but they do not necessarily narrow. Stenosis
and occlusion are most likely the consequence of plaque
rupture and thrombosis. This is illustrated by a study
reporting that Lp(a) was associated with thrombosis
[28], stenosis, and occlusion, but not plaque burden [29].
In multiple regression models, Lp(a) was found to be a
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significant independent predictor of stenosis (p < 0.001)
and vessel occlusion (p = 0.02), but not plaque area [29].
An increase in stenosis but not plaque volume may be
explained by effects of TMAO on arterial thrombosis
[30–33]. In our study, even though plaque stenosis was
not a pre-specified outcome, the finding remains concerning and important for potential harm.
We found a greater increase in stenosis in both arms
in the London site participants, compared to the Kingston site. The London site had a higher proportion of
participants with a history of stroke/TIA (55% vs 11%,
p < 0.001), while the Kingston site had a higher proportion of participants with a history of MI (41% vs 11%,
p = 0.001). TMAO is believed to enhance platelet hyperreactivity and increase thrombosis risk. TMAO may be
associated with changes in plaque composition or shape.
The supplement industry is estimated to be worth nearly
$300 billion globally, and nearly half of U.S adults report
taking at least one vitamin or supplement [34], many doing
so without any specific clinician recommendation. Individuals often consume L-C for boosting energy or build
muscle strength. However, although this supplement is
easily available without a prescription in energy drinks,
health food stores, or as a protein supplement, this does
not mean that it is necessarily benign or free from adverse
effects. While secondary outcomes should be interpreted
cautiously in the face of overall non-significant results for
the primary outcome, our findings suggest potential harm
with L-C supplements, both for worsening cardiometabolic risk factors (i.e., LDL-C) and for atherosclerosis progression (i.e., stenosis). This raises concern about the use
of these supplements, particularly in patients at high cardiovascular risk such as those with the MetS.
Limitations

The sample size and duration of studies may appear
small, but when measuring TPV compared to CIMT
our sample size was appropriately powered for the
primary outcome [35]. Based on our previous study
of effect of atorvastatin on TPV [16], our sample size
was calculated to have sufficient power to show an
effect size of (5%) within 6 months. However, the
study was not powered to formally test effect modification between sub-group. Although all participants
in this study had MetS, their underlying cardiovascular disease history may have different mechanisms and
associations with stroke vs MI, requiring further investigation. Finally, though carotid plaque assessment
by ultrasound is a surrogate marker, it has now been
validated as a meaningful predictor of cardiovascular
events, with robust recommendations on the performance, standardization and clinical utility in the prediction of important atherosclerotic outcomes [19].
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Conclusions
In this randomized, double-blinded, placebo-controlled
trial of adults with the MetS, we did not observe a
change in total plaque volume among participants
treated with L-C for 6 months. However, secondary
analyses indicated a greater progression of carotid stenosis with L-C supplementation compared to placebo.
The adverse effect of L-C was greater in participants
with low meat consumption than in those with high
meat consumption. These findings raise concerns with
respect to use of L-C as a therapy or supplement in
individuals with MetS.
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